This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Pediatric Research Equity Act | |
|---|---|
| Name | Pediatric Research Equity Act |
| Enacted | 2003 |
| Enacted by | United States Congress |
| Effective | 2003 |
| Amended | 2007 |
| Summary | Requires pediatric studies for certain drug and biological product applications to the United States Food and Drug Administration under specified conditions |
Pediatric Research Equity Act The Pediatric Research Equity Act (PREA) is a United States statute that authorizes the United States Food and Drug Administration to require pediatric studies of certain drugs and biological products as a condition of product approval. Enacted during the tenure of the 108th United States Congress and signed into law by President George W. Bush, PREA interacts with other statutes such as the Best Pharmaceuticals for Children Act and provisions of the Food, Drug, and Cosmetic Act. The law has shaped interactions among stakeholders including the Pharmaceutical Research and Manufacturers of America, academic centers like Children's Hospital of Philadelphia, and regulators at the National Institutes of Health.
PREA emerged amid growing attention from legislators such as Representative Edward Markey and Senator Patty Murray to address gaps identified by clinicians from institutions like Boston Children's Hospital and advocates including the March of Dimes. Debates in committees such as the United States House Committee on Energy and Commerce and the United States Senate Committee on Health, Education, Labor, and Pensions referenced earlier pediatric initiatives from the 1990s and international efforts at the European Medicines Agency. Proponents cited reports from the Institute of Medicine and investigations by the Government Accountability Office documenting widespread off-label pediatric prescribing in settings like pediatric oncology and neonatology. PREA was enacted alongside amendments to the Food and Drug Administration Modernization Act of 1997 and later reauthorizations in the era of the 110th United States Congress.
PREA authorizes the United States Food and Drug Administration to require pediatric assessments when an application seeks approval for new active moieties, new indications, new dosage forms, new dosing regimens, or new routes of administration relevant to pediatric populations. The statute establishes timelines and pediatric study plan expectations involving sponsors typically comprising companies represented by Pfizer, Merck & Co., and other firms registered with the Securities and Exchange Commission. PREA interacts with exclusivity incentives under the Best Pharmaceuticals for Children Act and exceptions such as waivers or deferrals based on scientific rationale presented by applicants and reviewed by reviewers from the Center for Drug Evaluation and Research. The law specifies pediatric age groups, considerations for rare conditions such as those treated by St. Jude Children's Research Hospital, and requirements for submission of pediatric study plans during investigational new drug applications or new drug applications with oversight from the Food and Drug Administration staff.
PREA has influenced clinical trial portfolios at academic sites like Duke University School of Medicine and industry-sponsored networks such as the Clinical and Translational Science Awards Program. The requirement for pediatric assessments has catalyzed pediatric pharmacokinetic and safety studies in fields like pediatric cardiology, pediatric oncology, and neonatology and changed labeling for medicines produced by manufacturers including Johnson & Johnson and GlaxoSmithKline. Outcomes have included new pediatric dosing information in product labeling, trial designs coordinated with institutional review boards at centers such as Johns Hopkins Hospital, and collaborations with consortia like the Pediatric Trials Network. PREA-driven evidence has informed clinical practice guidelines from professional bodies including the American Academy of Pediatrics.
Implementation relies on coordination between sponsor companies, regulatory reviewers at the United States Food and Drug Administration, and clinical investigators at sites like Children's National Hospital. The agency enforces PREA through issuance of pediatric study requests, review of pediatric study plans, and, when necessary, approval conditions or letters tied to marketing applications reviewed by panels such as the Advisory Committee for Pharmaceutical Science. Oversight intersects with programs at the National Institutes of Health and international regulatory counterparts including the European Medicines Agency to harmonize age stratifications and study methodologies. Compliance is monitored via submission of study reports and labeling changes handled by reviewers in the Center for Biologics Evaluation and Research where applicable.
Critics including trade groups like the Pharmaceutical Research and Manufacturers of America and some academic commentators at institutions like Yale School of Medicine have argued that PREA can impose burdensome timelines and increase costs for sponsors, potentially affecting research priorities for conditions prevalent in adults. Legal and policy disputes have arisen regarding the scope of PREA’s authority, waiver and deferral standards, and interactions with pediatric exclusivity provisions overseen by committees in the United States Congress. Patient advocates from organizations such as Families for Better Care and commentators in journals affiliated with Harvard Medical School have debated trade-offs between accelerating pediatric data generation and protecting vulnerable pediatric research subjects under standards like those applied by institutional review boards at Massachusetts General Hospital.
PREA is part of a broader legislative framework including the Best Pharmaceuticals for Children Act, the Food, Drug, and Cosmetic Act, and reauthorization efforts in sessions of the United States Congress. Internationally, PREA’s approach has parallels with pediatric regulations at the European Medicines Agency and guidance from bodies such as the World Health Organization on pediatric formulations. Policy discussions often reference reports from the Institute of Medicine and evaluations by the Government Accountability Office when considering amendments or harmonization with incentives like patent extensions tracked by the United States Patent and Trademark Office.